Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease
April 13, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 13, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2015 Financial Results
March 14, 2016 08:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference on March 8th
March 02, 2016 17:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 02, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Rockwell Medical Enters Into Exclusive License Agreement With Wanbang Biopharmaceutical Co., Ltd. to Commercialize Triferic® in China
February 16, 2016 08:00 ET
|
Rockwell Medical, Inc.
WIXOM, Mich., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney...
Proteon Therapeutics to Present at the 2016 BIO CEO & Investor Conference February 8th
February 02, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients...
Proteon Therapeutics to Present at the Oppenheimer 26th Annual Healthcare Conference December 9th
December 02, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Stifel 2015 Healthcare Conference on November 17th
November 13, 2015 07:45 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Third Quarter 2015 Financial Results
November 12, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
-Enrollment in PATENCY-1 Completed Ahead of Schedule-
-Data from PATENCY-1 Expected in December 2016-
-Proteon to Hold Research and Development Day in New York on November 20-
WALTHAM, Mass.,...
Proteon Therapeutics to Host Research and Development Day on November 20, 2015
November 09, 2015 11:58 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Completes Enrollment in PATENCY-1, First Phase 3 Clinical Study of Investigational Vonapanitase
November 02, 2015 16:15 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...